Interesting T2DM: Pharmacotherapy & Obesity Outcomes
Our April list includes CV events with DPP-4 or SGLT2 inhibitors vs. insulin, and impact of obesity on nonalcoholic fatty liver disease and thyroid function.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
SUBSCRIBE: eNewsletter
Coverage of The Endocrine Society's annual meeting, that took place April 1-4 in Orlando, FL.
Our April list includes CV events with DPP-4 or SGLT2 inhibitors vs. insulin, and impact of obesity on nonalcoholic fatty liver disease and thyroid function.
Could corticosteroid use put your patients at a greater risk of metabolic syndrome?
Men’s health studies presented at ENDO 2017 included a possible prostate cancer treatment and the potential of hormone therapy to prevent frailty.
Three studies from ENDO 2017 focused on improving patient care through brain stimulation, an artificial pancreas system, and videoconferencing.
Researchers sought to discover the specific physiological pathways of fibroblast growth factor 21.
Research presented at ENDO 2017 explored options to reduce complications in patients with diabetes and microalbuminuria and patients with cystic fibrosis.
Studies presented at ENDO 2017 examined the impact of sleep disorders on gestational diabetes, bone formation, and adolescents with and without diabetes.
Researchers investigated possible differences in the function of the striatum both before and after the development of obesity.
You won’t want to miss these top sessions and new features at this year’s Endocrinology Society’s annual meeting, April 1-4, in Orlando, FL.